SkinHealth Swings to Loss, But Margins Hold

SkinHealth (SKIN) reported fiscal 2026 Q2 earnings on August 7, 2026. Results missed expectations as revenue declined 7.8% year-over-year, driven by cautious provider capital investment. The company lowered its full-year revenue guidance to $280M-$290M but raised adjusted EBITDA expectations to $39M-$46M, citing improved margins and cost discipline despite top-line headwinds.

Revenue

Total revenue decreased by 7.8% to $72.11 million in 2026 Q2, down from $78.19 million in the prior-year period. Within this total, consumables generated $53.86 million in revenue, while delivery systems contributed $18.25 million.

Earnings/Net Income

SkinHealth swung to a loss of $0.02 per share in 2026 Q2 from a profit of $0.16 per share in 2025 Q2 (112.5% negative change). Meanwhile, the company reported a net loss of $-2.67 million in 2026 Q2, reflecting a 113.5% deterioration from the net income of $19.71 million achieved in 2025 Q2. This significant earnings decline reflects challenging market conditions and reduced equipment sales volumes.

Price Action

The stock price of SkinHealth has edged up 1.54% during the latest trading day, has dropped 3.57% during the most recent full trading week, and has plummeted 37.05% month-to-date.

Post-Earnings Price Action Review

Following the earnings release, SkinHealth’s stock exhibited mixed intraday momentum but suffered significant monthly losses. While the share price saw a slight 1.54% increase on the latest trading day, it declined 3.57% over the most recent full trading week. More critically, the stock has plummeted 37.05% month-to-date, reflecting investor concern over the 113.5% deterioration in net income and revised lower revenue guidance. Despite the company’s emphasis on margin improvement, the substantial drop in top-line performance and the swing to a net loss have weighed heavily on market sentiment, overshadowing the positive adjusted EBITDA outlook.

CEO Commentary

Pedro Malha, President and Chief Executive Officer, acknowledged persistent sales pressures while highlighting that adjusted EBITDA significantly exceeded guidance due to enhanced gross margins and disciplined operating expense management. Strategic priorities remain focused on strengthening the core Hydrafacial franchise, increasing installed base productivity, and expanding the portfolio with complementary technologies. Malha expressed confidence that the Company’s trusted brand, global provider network, and recurring consumables business position SkinHealth Systems to deliver sustainable, diversified long-term growth despite current market challenges.

Guidance

The Company has revised its fiscal 2026 financial guidance to reflect continued sales pressure and ongoing cost discipline. For the third quarter of 2026, net sales are projected between $65 million and $70 million, with adjusted EBITDA expected between $5 million and $7 million. For the full fiscal year 2026, net sales are guided at $280 million to $290 million, and adjusted EBITDA is projected at $39 million to $46 million. These estimates presume no material deterioration in general market conditions, excluding unannounced acquisitions, dispositions, or financings.

Additional News

In related corporate developments, SkinHealth is preparing for a shareholder vote on a reverse stock split scheduled for September 22. This move aims to address potential delisting risks associated with the stock’s recent price decline below regulatory minimums. Management has indicated that the split is necessary to maintain compliance with Nasdaq listing requirements following the significant volatility in the share price. Additionally, the company continues to navigate a cautious capital investment environment among its provider network, which has impacted equipment sales. To mitigate this, SkinHealth recently introduced a U.S. device rental program designed to reduce upfront financial barriers for providers. This initiative, facilitated by a third-party financing partner, allows the company to recognize revenue upfront while enabling qualified providers to access Hydrafacial devices without immediate capital expenditure. The program is not expected to cannibalize existing sales but rather to expand the installed base among those previously restricted by financing constraints.